Allurion Reports 23% Weight Loss and Increased Lean Mass With Combined Balloon and Low-Dose Tirzepatide Therapy

Reuters11-25

Allurion Reports 23% Weight Loss and Increased Lean Mass With Combined Balloon and Low-Dose Tirzepatide Therapy

Allurion Technologies Holdings Inc. has announced initial results from a case series evaluating the combination of the Allurion Program with low-dose tirzepatide therapy. The study involved 76 patients who received the Allurion Smart Capsule followed by low-dose tirzepatide, with doses ranging from 2.5mg to a maximum of 5.0mg, which is lower than standard tirzepatide dosing. After 12 months, participants experienced an average total body weight loss of 23% and a 14% increase in lean body mass as a percentage of total body weight. All patients remained adherent to tirzepatide throughout the study period. Additional data from this combination approach is being collected and is expected to be presented at upcoming medical meetings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allurion Technologies Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251125509141) on November 25, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2586248479?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-25 22:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586248479","market":"us","top_or_hot":-1,"title":"Allurion Reports 23% Weight Loss and Increased Lean Mass With Combined Balloon and Low-Dose Tirzepatide Therapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Allurion Reports 23% Weight Loss and Increased Lean Mass With Combined Balloon and Low-Dose Tirzepatide Therapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ALUR\">Allurion Technologies</a> Holdings Inc. has announced initial results from a case series evaluating the combination of the Allurion Program with low-dose tirzepatide therapy. The study involved 76 patients who received the Allurion Smart Capsule followed by low-dose tirzepatide, with doses ranging from 2.5mg to a maximum of 5.0mg, which is lower than standard tirzepatide dosing. After 12 months, participants experienced an average total body weight loss of 23% and a 14% increase in lean body mass as a percentage of total body weight. All patients remained adherent to tirzepatide throughout the study period. Additional data from this combination approach is being collected and is expected to be presented at upcoming medical meetings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allurion Technologies Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251125509141) on November 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allurion Reports 23% Weight Loss and Increased Lean Mass With Combined Balloon and Low-Dose Tirzepatide Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllurion Reports 23% Weight Loss and Increased Lean Mass With Combined Balloon and Low-Dose Tirzepatide Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-25 22:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Allurion Reports 23% Weight Loss and Increased Lean Mass With Combined Balloon and Low-Dose Tirzepatide Therapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ALUR\">Allurion Technologies</a> Holdings Inc. has announced initial results from a case series evaluating the combination of the Allurion Program with low-dose tirzepatide therapy. The study involved 76 patients who received the Allurion Smart Capsule followed by low-dose tirzepatide, with doses ranging from 2.5mg to a maximum of 5.0mg, which is lower than standard tirzepatide dosing. After 12 months, participants experienced an average total body weight loss of 23% and a 14% increase in lean body mass as a percentage of total body weight. All patients remained adherent to tirzepatide throughout the study period. Additional data from this combination approach is being collected and is expected to be presented at upcoming medical meetings.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allurion Technologies Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251125509141) on November 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999006597.SGD","symbol_name":"United China-India Dynamic Growth SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251125:nNDL9GBfDm:1","article_id":"2586248479","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2586248479","pubTimestamp":1764080711,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Allurion Technologies Holdings Inc. has announced initial results from a case series evaluating the combination of the Allurion Program with low-dose tirzepatide therapy. The study involved 76 patients who received the Allurion Smart Capsule followed by low-dose tirzepatide, with doses ranging from 2.5mg to a maximum of 5.0mg, which is lower than standard tirzepatide dosing. After 12 months, participants experienced an average total body weight loss of 23% and a 14% increase in lean body mass as a percentage of total body weight. All patients remained adherent to tirzepatide throughout the study period. Additional data from this combination approach is being collected and is expected to be presented at upcoming medical meetings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999006597.SGD":"United China-India Dynamic Growth SGD","ALUR":"ALLURION TECHNOLOGIES","BK1608":"元宇宙概念","BK1167":"电子制造服务","BK4192":"特殊消费者服务","02018":"瑞声科技","SG9999014674.SGD":"Nikko AM All China Equity A SGD","BK1607":"新IT概念","BK1504":"苹果概念","BK1500":"做空集合股"},"translate_title":"Allurion报告联合球囊和低剂量替西帕肽治疗可使体重减轻23%，瘦体重增加","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02018":0.9,"ALUR":0.9},"content_text":"Allurion Reports 23% Weight Loss and Increased Lean Mass With Combined Balloon and Low-Dose Tirzepatide Therapy\n    \n\nAllurion Technologies Holdings Inc. has announced initial results from a case series evaluating the combination of the Allurion Program with low-dose tirzepatide therapy. The study involved 76 patients who received the Allurion Smart Capsule followed by low-dose tirzepatide, with doses ranging from 2.5mg to a maximum of 5.0mg, which is lower than standard tirzepatide dosing. After 12 months, participants experienced an average total body weight loss of 23% and a 14% increase in lean body mass as a percentage of total body weight. All patients remained adherent to tirzepatide throughout the study period. Additional data from this combination approach is being collected and is expected to be presented at upcoming medical meetings.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allurion Technologies Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251125509141) on November 25, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2586248479","isCrawlerRequest":true}